Eosinophilic Asthma Latest Advances

Find the Latest Research About Eosinophilic Asthma

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1794 publications

Efficacy of benralizumab in reducing cough and/or dyspnea frequency, and improving cough-specific health-related quality of life in patients with severe eosinophilic asthma in Asia.

Efficacy of benralizumab in reducing cough and/or dyspnea frequency, and improving cough-specific health-related quality of life in patients with severe eosinophilic asthma in Asia.

Journal: Therapeutic advances in respiratory disease
Published: August 28, 2026

Small airway dysfunction and associated clinical characteristics in severe asthma under omalizumab and mepolizumab treatment.

Small airway dysfunction and associated clinical characteristics in severe asthma under omalizumab and mepolizumab treatment.

Journal: Asian Pacific journal of allergy and immunology
Published: August 23, 2026

Three-year sustained remission with mepolizumab in a rare eosinophilic disease: idiopathic chronic eosinophilic pneumonia.

Three-year sustained remission with mepolizumab in a rare eosinophilic disease: idiopathic chronic eosinophilic pneumonia.

Journal: European clinical respiratory journal
Published: August 13, 2026

Dexpramipexole alleviates chronic allodynia from sciatic neuropathy and reduces spinal interferon-γ and other proinflammatory cytokines in spinal cord and dorsal root ganglia in mice.

Dexpramipexole alleviates chronic allodynia from sciatic neuropathy and reduces spinal interferon-γ and other proinflammatory cytokines in spinal cord and dorsal root ganglia in mice.

Journal: Medical research archives
Published: August 11, 2026

Effectiveness of mepolizumab in eosinophilic asthma and chronic rhinosinusitis with nasal polyps.

Effectiveness of mepolizumab in eosinophilic asthma and chronic rhinosinusitis with nasal polyps.

Journal: Rhinology
Published: August 11, 2026

Depemokimab-ulaa: A Long-Acting Interleukin-5 Inhibitor.

Depemokimab-ulaa: A Long-Acting Interleukin-5 Inhibitor.

Journal: The Annals of pharmacotherapy
Published: August 06, 2026

IL-5 biology and eosinophil regulation: Advances, resistance pathways and future directions.

IL-5 biology and eosinophil regulation: Advances, resistance pathways and future directions.

Journal: Respiratory medicine
Published: July 20, 2026

Benralizumab effectiveness in a real-world Portuguese severe eosinophilic asthma population: BETREAT study.

Benralizumab effectiveness in a real-world Portuguese severe eosinophilic asthma population: BETREAT study.

Journal: Pulmonology
Published: July 17, 2026

Diagnostic and Therapeutic Challenges in Asthma and Chronic Obstructive Pulmonary Disease Overlap: A Four-Patient Case Series.

Diagnostic and Therapeutic Challenges in Asthma and Chronic Obstructive Pulmonary Disease Overlap: A Four-Patient Case Series.

Journal: Cureus
Published: July 15, 2026

Sustained asthma control and remission in real-world patients with severe eosinophilic asthma receiving benralizumab: XALOC-2.

Sustained asthma control and remission in real-world patients with severe eosinophilic asthma receiving benralizumab: XALOC-2.

Journal: The Journal of asthma : official journal of the Association for the Care of Asthma
Published: July 01, 2026

Increased induced sputum ITGB5 expression was correlated with airway inflammation and lung function in asthma.

Increased induced sputum ITGB5 expression was correlated with airway inflammation and lung function in asthma.

Journal: The Journal of asthma : official journal of the Association for the Care of Asthma
Published: June 29, 2026

Adhesion molecules and T cell imbalance in severe eosinophilic asthma: Insights from anti-IL-5R treatment.

Adhesion molecules and T cell imbalance in severe eosinophilic asthma: Insights from anti-IL-5R treatment.

Journal: Pulmonology
Published: June 22, 2026
Showing 1-12 of 1,794

Last Updated: 09/26/2026